---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-029370"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:10:53.627840+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharma receives Nasdaq notice for non-compliance with equity requirement

## Summary
- Notice based on 10-K for FY 2024; stockholders' equity fell below $2.5M minimum.
- Company has 45 days (until May 9, 2025) to submit a Compliance Plan to Nasdaq.
- If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.
- If plan rejected, common stock subject to delisting; company can appeal to Hearing Panel.
- Company cautions no assurance that plan will be accepted or compliance regained.

## SEC filing metadata
- accession: 0001104659-25-029370
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/0001104659-25-029370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465925029370/tm2510590d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-029370
- JSON: https://secwatch.observer/filing/0001104659-25-029370.json
- Plain text: https://secwatch.observer/filing/0001104659-25-029370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.